Literature DB >> 2425950

Interferon therapy in cancer: from imaginon to interferon.

D Goldstein, J Laszlo.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2425950

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  40 in total

Review 1.  Interferons 1992. How much of the promise has been realised?

Authors:  M A Volz; C H Kirkpatrick
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

Review 2.  Recombinant DNA and surgery.

Authors:  J M Brown; A H Harken; J B Sharefkin
Journal:  Ann Surg       Date:  1990-08       Impact factor: 12.969

Review 3.  Interferon for treatment: the dust settles.

Authors:  D Galvani; S D Griffiths; J C Cawley
Journal:  Br Med J (Clin Res Ed)       Date:  1988-06-04

4.  Cytotoxic effects of alpha- and gamma-interferon and tumor necrosis factor in human bladder tumor cell lines.

Authors:  H B Niell; A M Mauer; D Rademacher
Journal:  Urol Res       Date:  1994

Review 5.  Interferon-alpha in malignant and viral diseases. A review.

Authors:  R T Dorr
Journal:  Drugs       Date:  1993-02       Impact factor: 9.546

6.  Normalization Cancer Immunotherapy for Melanoma.

Authors:  Matthew D Vesely; Lieping Chen
Journal:  J Invest Dermatol       Date:  2020-02-22       Impact factor: 8.551

7.  Inhibition of dihydropyrimidine dehydrogenase by alpha-interferon: experimental data on human tumor cell lines.

Authors:  G Milano; J L Fischel; M C Etienne; N Renée; P Formento; A Thyss; M H Gaspard; L Thill; D Cupissol
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  IFNαR signaling in effector but not regulatory T cells is required for immune dysregulation during type I IFN-dependent inflammatory disease.

Authors:  Shivani Srivastava; Lisa K Koch; Daniel J Campbell
Journal:  J Immunol       Date:  2014-08-04       Impact factor: 5.422

9.  Interferon gamma but not tumor necrosis factor alpha decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells.

Authors:  Y Tomita; H Watanabe; H Kobayashi; T Nishiyama; S Tsuji; M Fujiwara; S Sato
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

10.  Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model.

Authors:  M Sivanandham; S D Scoggin; N Tanaka; M K Wallack
Journal:  Cancer Immunol Immunother       Date:  1994-04       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.